Literature DB >> 21294670

Aripiprazole for the treatment of irritability associated with autism.

Cristan Ann Farmer1, Michael G Aman.   

Abstract

INTRODUCTION: Irritability (including tantrums, aggression and moodiness) is often associated with autistic disorder. Children with autism are frequently prescribed atypical antipsychotic medications for these behaviors. Although multiple agents have been found to be effective, the safety and tolerability of each antipsychotic may be the determining factor in its selection. AREAS COVERED: The pharmacokinetics, pharmacodynamics, safety and efficacy data on aripiprazole for the treatment of irritability associated with autism are discussed. Knowledge of the mechanism of action, advantages and disadvantages relative to other atypical antipsychotics, and an appreciation of the efficacy of aripiprazole when used to treat irritability in autism is also explored in this paper. EXPERT OPINION: Aripiprazole may have a more favorable side-effect profile than another commonly prescribed medication, risperidone, because of its unique mechanism of action. It seems to be effective in treating irritability associated with autism, but more research is needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21294670      PMCID: PMC3670599          DOI: 10.1517/14656566.2011.557661

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  20 in total

1.  Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder.

Authors:  Michael G Aman; William Kasper; George Manos; Suja Mathew; Ronald Marcus; Randall Owen; Raymond Mankoski
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-10       Impact factor: 2.576

2.  Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies.

Authors:  Adelaide S Robb; Candace Andersson; Elizabeth E Bellocchio; George Manos; Carlos Rojas-Fernandez; Suja Mathew; Ronald Marcus; Randall Owen; Raymond Mankoski
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification.

Authors:  Luc Lecavalier
Journal:  J Autism Dev Disord       Date:  2006-11

4.  Aripiprazole for maladaptive behavior in pervasive developmental disorders.

Authors:  Kimberly A Stigler; David J Posey; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2004       Impact factor: 2.576

5.  Pervasive developmental disorders in preschool children: confirmation of high prevalence.

Authors:  Suniti Chakrabarti; Eric Fombonne
Journal:  Am J Psychiatry       Date:  2005-06       Impact factor: 18.112

6.  Medication patterns in patients with autism: temporal, regional, and demographic influences.

Authors:  Michael G Aman; Kristen S L Lam; Mary E Van Bourgondien
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-02       Impact factor: 2.576

7.  Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.

Authors:  Kimberly A Stigler; Jonathan T Diener; Arlene E Kohn; Lang Li; Craig A Erickson; David J Posey; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

8.  Focus on aripiprazole: a review of its use in child and adolescent psychiatry.

Authors:  Masa'il Greenaway; Dean Elbe
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-08

Review 9.  Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.

Authors:  Anthony DeLeon; Nick C Patel; M Lynn Crismon
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393

10.  A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.

Authors:  Ronald N Marcus; Randall Owen; Lisa Kamen; George Manos; Robert D McQuade; William H Carson; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-11       Impact factor: 8.829

View more
  12 in total

1.  A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.

Authors:  Ahmad Ghanizadeh; Aliakbar Sahraeizadeh; Michael Berk
Journal:  Child Psychiatry Hum Dev       Date:  2014

Review 2.  Aripiprazole for autism spectrum disorders (ASD).

Authors:  Lauren E Hirsch; Tamara Pringsheim
Journal:  Cochrane Database Syst Rev       Date:  2016-06-26

Review 3.  The role of monoamine oxidase A in aggression: Current translational developments and future challenges.

Authors:  Sean C Godar; Paula J Fite; Kenneth M McFarlin; Marco Bortolato
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-01-09       Impact factor: 5.067

Review 4.  Pharmacotherapy for the core symptoms in autistic disorder: current status of the research.

Authors:  Cristan Farmer; Audrey Thurm; Paul Grant
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

Review 5.  Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms.

Authors:  Rahul Singh; Ryan C Turner; Linda Nguyen; Kartik Motwani; Michelle Swatek; Brandon P Lucke-Wold
Journal:  Behav Neurol       Date:  2016-12-15       Impact factor: 3.342

6.  Prescription Trends of Psychotropics in Children and Adolescents with Autism Based on Nationwide Health Insurance Data.

Authors:  Minha Hong; Seung Yup Lee; Juhee Han; Jin Cheol Park; Yeon Jung Lee; Ram Hwangbo; Hyejung Chang; Seong Woo Cho; Soo Young Bhang; Bongseog Kim; Jun Won Hwang; Geon Ho Bahn
Journal:  J Korean Med Sci       Date:  2017-10       Impact factor: 2.153

7.  Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea.

Authors:  Young Sup Woo; In Hee Shim; Sang-Yeol Lee; Dae-Bo Lee; Moon-Doo Kim; Young-Eun Jung; Jonghun Lee; Seunghee Won; Duk-In Jon; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-05-31       Impact factor: 2.582

8.  Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence.

Authors:  Ramit Sharma; Saloni Rahi; Sidharth Mehan
Journal:  Toxicol Rep       Date:  2019-11-05

Review 9.  New experimental treatments for core social domain in autism spectrum disorders.

Authors:  Roberto Canitano
Journal:  Front Pediatr       Date:  2014-06-20       Impact factor: 3.418

Review 10.  Aripiprazole for treating irritability in children & adolescents with autism: A systematic review.

Authors:  Ahmad Ghanizadeh; Sylvie Tordjman; Nematollah Jaafari
Journal:  Indian J Med Res       Date:  2015-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.